EU Clears Novo Nordisk's Haemophilia A Drug FREHEMGO

what happened

According to TradingView, the European Commission has granted marketing authorization to FREHEMGO (denecimig), a next-generation treatment from Novo Nordisk. It is meant for routine prevention of bleeding episodes in adults and children with haemophilia A, whether or not inhibitors are present. Haemophilia A is a rare inherited disorder caused by a shortage of clotting factor VIII, and without control it can lead to prolonged bleeding and joint damage.

The drug is a bispecific antibody that mimics factor VIIIa and is given under the skin. A single-use prefilled pen allows injections every seven days, every fourteen days or every thirty days, so clinicians and patients can shape a schedule to their own needs. Clinical data showed the therapy prevents or reduces bleeding regardless of inhibitor status.

Novo Nordisk plans to bring FREHEMGO to the first European markets within the coming year. The treatment is already approved in Saudi Arabia, and applications are under review by the US FDA and other regulators.

why it matters

For markets the news is fairly narrow: the approval adds a product to Novo Nordisk's haemophilia range and widens access to treatment in Europe. Investors are likely to view it as one piece of the company's wider portfolio. The source reports that NVO closed Friday at $41.63, up 2.41%, and edged lower after hours.

market impact

Novo Nordisk shares: new haemophilia approval broadens the portfolio, with a limited effect

tags

instruments